Tirzepatide dosage: the ramp schedule clinics actually use in 2026

The dose schedule is the thing most tirzepatide write-ups gloss over. People quote the 20% weight-loss number from SURMOUNT-1 and skip straight past the part where that number was earned: 72 weeks of disciplined titration starting at 2.5 mg and stepping up once a month. Skip the ramp and you get nausea-driven discontinuation. Rush the ramp and you get the same thing worse. Here is what a standard protocol actually looks like, what the research says, and where clinics deviate from the label.

The SURMOUNT-1 ramp

SURMOUNT-1 (Jastreboff et al., NEJM 2022) used a strict monthly step-up. Every participant started at 2.5 mg once weekly for four weeks. At week five, dose increased to 5 mg. At week nine, 7.5 mg. At week thirteen, 10 mg. From week seventeen, the participant held their assigned target dose (5, 10, or 15 mg) for the remaining 55 weeks.

Why the ramp? GI tolerability. Tirzepatide activates two gut receptors (GIP and GLP-1). Both delay gastric emptying, which is the mechanism that makes food feel less appetizing at dose, and also the mechanism that causes nausea, reflux, constipation, and sometimes vomiting when dose is introduced too fast. The monthly step-up gives the gut time to adapt.

Trials that skipped the ramp (or used shorter intervals) saw higher discontinuation from GI side effects without much acceleration in weight loss. The four-week-per-step schedule is not arbitrary; it is the cadence that preserves adherence.

What your pharmacy actually sells

The brand Mounjaro pen is manufactured in fixed doses: 2.5, 5, 7.5, 10, 12.5, and 15 mg. One pen, one weekly dose. When you step up, your prescription changes to the next-strength pen.

Compounded tirzepatide is a different animal. The compounding pharmacy dispenses a vial of multi-dose solution (typically 10 mg/mL concentration) and you draw up the weekly dose yourself with a syringe. This is cheaper and more flexible but requires you to do reconstitution math correctly. A 2.5 mg dose from a 10 mg/mL vial is 0.25 mL. A 5 mg dose is 0.5 mL. Getting this wrong is the single most common compounded-tirzepatide injury we see reported.

If you are starting a compounded protocol, write down the math on a card and tape it inside your fridge door. Sounds excessive. Prevents the thing.

Standard ramp, week by week

For a typical adult starting tirzepatide with a target of 10 mg:

Week 1 to 4: 2.5 mg weekly. This is the starter dose. No weight loss expected. Nausea is likely at first injection, usually eases by day three. Stay hydrated. Keep meals smaller and less fatty for the first week.

Week 5 to 8: 5 mg weekly. This is the first "active" dose. Meaningful appetite suppression begins here. Expect 1 to 2 kg weight loss over this block, depending on starting weight.

Week 9 to 12: 7.5 mg weekly. GI side effects may return briefly after the step-up; they are usually milder than the 5 mg introduction because the gut has adapted.

Week 13 to 16: 10 mg weekly. This is a common plateau for people in the 80 to 95 kg starting range who are not aiming for maximum weight loss. Roughly half of SURMOUNT-1 participants held at 10 mg or below for the full trial.

Week 17 onward: if 10 mg is not producing the effect you want, step to 12.5 mg at week 17, then 15 mg at week 21. If 10 mg is enough, hold.

When clinics deviate

A few common deviations from the label:

Some Bangkok clinics compress the ramp to a two-week step-up. The logic is that Thai patients are smaller on average than SURMOUNT-1 participants (mean starting weight 105 kg) and hit target blood levels faster. There is no published study supporting this. If your clinic proposes a two-week ramp, ask why. The honest answer is usually "other patients tolerate it" which is not the same as "the data supports it."

Other clinics start at 5 mg to skip the "dead month." Do not do this unless you are absolutely sure you tolerate GLP-1 class drugs. The nausea curve at 5 mg is much steeper than at 2.5 mg. One in ten people stops in the first month when dose starts too high.

Some concierge practices use micro-dosing (0.5 to 1.5 mg weekly) for longevity rather than weight-loss patients. This is off-label and the weight-loss data does not apply. Micro-doses are real in the sense that they produce measurable GLP-1 activity. Whether they produce the cardiovascular or metabolic benefit attributed to full-dose tirzepatide is unknown. The literature is single-digit published trials.

How long you should stay on it

This is where the marketing gets thin. SURMOUNT-1 ran 72 weeks. SURMOUNT-4 (Aronne et al., JAMA 2023) followed up: participants who continued tirzepatide after the initial lead-in kept losing weight for another 52 weeks. Participants randomized to placebo after the lead-in regained roughly 14 percentage points on average within 12 months.

The practical implication is that tirzepatide is not a 72-week intervention followed by a maintenance phase. If you stop, the weight comes back. This is the compound working as designed, not a failure.

For a long-term user, expect the protocol to look like:

• 12-week ramp (weeks 1 to 13)
• 6 to 12 months at target dose for weight loss (weeks 13 to 64)
• Maintenance at the same or a slightly lower dose indefinitely

Some clinicians drop maintenance patients from 10 mg to 5 mg once target weight holds steady for three months. The data for this step-down is sparse but the pharmacokinetics support it. Half the receptor activity at a quarter the drug exposure. Worth discussing with your prescriber if monthly cost is the constraint.

What to watch for

Three signals that mean the ramp needs to slow down: 1. Nausea lasting more than five days after a dose step-up 2. Vomiting more than once in a 24-hour window 3. Unintentional weight loss faster than 1.5 kg per week for more than two weeks running

Any of those and your clinician should either hold the current dose for an extra four weeks or drop you back one step. Pushing through is not a badge. It is how people land in the "I quit tirzepatide at week six" bucket.

The honest short version

The ramp is 2.5 mg week 1-4, then 5 mg, then 7.5 mg, then 10 mg in four-week blocks. Hold at target. Do not start at 5 mg unless you have been through it before. Do not trust compressed ramps unless the data warrants it. Plan for long-term use, not a finite course. Budget for maintenance accordingly.

If you want a printable schedule with monthly cost estimates in USD and THB across four purchase channels, our tirzepatide calculator has the full 12-week view.

---

Citations: Jastreboff et al., NEJM 2022 (SURMOUNT-1, n=2,539, 72 weeks); Aronne et al., JAMA 2023 (SURMOUNT-4, n=670); Eli Lilly prescribing information for Mounjaro and Zepbound; Attia AMA #64 on protein and resistance training during GLP-1 use.